Medigen Vaccine Biologics Corp.

Medigen Vaccine Biologics Corp.

TTPEX:6547
45.00
TWD
-0.75
(-1.64%)
-0.51EPS
14.94BMarket Cap
Mar 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
0.04
15.26
1.13
1.19
1.84
1.87
1.77
Basic EPS, GAAP
-3.14
-1.04
-1.29
-1.2
-1.72
-2.09
-2.67
-2.42
6.56
-4.56
-3.53
-0.24
-0.86
-0.51
Free Cash Flow per Basic Share
-4.12
-9.37
-1.7
-3.59
-1.55
-1.72
-2.5
-2.5
2.07
-4.19
-1.59
0.02
-0.31
-0.67
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.65
6.24
7.78
7.75
7.26
6.77
5.77
10
14.76
15.34
11.71
11.71
10.58
10.81
Tangible Book Value per Share
2.12
5.69
7.27
7.33
6.89
6.47
5.51
9.81
14.59
15.2
11.59
11.62
10.52
10.76
Basic Weighted Avg Shares
24
101
141
175
198
228
232
278
215
323
328
329
329
325
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
1
12
3,281
365
390
606
613
574
Operating Margin (%)
- -
- -
- -
- -
- -
- -
-53,920.71
-6,638.4
29.37
-420.85
-311.54
-24.05
-43.33
-31.56
Depreciation Expense
9
12
13
19
83
101
118
122
113
128
131
136
142
148
Net Income, GAAP
-77
-105
-182
-210
-340
-476
-618
-674
1,410
-1,475
-1,160
-80
-282
-167
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-55,153.39
-5,859.74
42.98
-403.95
-297.68
-13.29
-45.94
-29.06
Working Capital
316
549
528
301
536
635
291
1,849
3,282
5,107
2,410
2,343
2,178
2,674
LT Debt
- -
85
245
311
506
434
682
186
184
1,944
254
300
270
1,080
Total Equity
458
1,079
1,344
1,470
1,521
1,612
1,367
3,141
4,676
5,029
3,847
3,850
3,479
3,555
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
23.52
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
34.57
- -
- -
- -
- -
- -
Return on Common Equity (%)
-26.22
-13.72
-15
-14.9
-22.76
-30.41
-41.47
-29.91
36.08
-30.39
-26.14
-2.09
-7.69
-4.62

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
14
22
23
LT Borrowings
- -
708
705
LT Finance Leases
270
368
376
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
329
329
329
Market Capitalization
12,410
18,837
14,942

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,363
2,822
2,799
Cash, Cash Equivalents & STI
1,777
2,173
2,044
Accounts Receivable, Net
130
116
127
Inventories
394
466
527
Total Current Liabilities
185
184
125
Payables & Accruals
- -
- -
- -
ST Debt
14
22
23
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.68%
4.67%
-9.63%
Free Cash Flow
-237.27%
-515.6%
-1,847.19%
Net Income, GAAP
-22.15%
-75.6%
250.11%
Sales/Revenue/Turnover
- -
5,677.51%
1.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
59
175
243
129
606
2025
115
145
206
147
613
2026
106
115
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.22
0.04
- -
-0.07
-0.24
2025
-0.06
-0.3
-0.07
-0.42
-0.86
2026
-0.09
0.07
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Leo Lee
Full Time Employees
1,226
Sector
Health technology
Industry
Biotechnology
Address
No. 68, Shengyi 3rd Road Zhubei KH Taiwan 30261
IPO Date
Aug 6, 2015
Business
Medigen Vaccine Biologics Corporation (6547.TWO) develops and manufactures vaccines and biopharmaceuticals targeting infectious diseases using cell-based technologies. The company offers ENVACGEN enterovirus A71 vaccine for preventing severe complications in children; MVC-COV1901 COVID-19 protein subunit vaccine authorized for emergency use in Taiwan and Paraguay; Fluvacgen trivalent influenza vaccine; and quadrivalent influenza vaccine in Phase III trials; alongside dengue vaccine post-Phase II, anti-RSV vaccine in Phase I, and pipelines for enterovirus D68 and multivalent Coxsackie enterovirus. It wholesales these products and medical devices primarily in Taiwan, Southeast Asia, and developing markets, with manufacturing in Hsinchu Biomedical Science Park, Zhubei City. Founded in 2012 and headquartered in Zhubei City, Hsinchu County, Taiwan, Medigen Vaccine Biologics operates as a subsidiary of Medigen Biotechnology Corp. In January 2025, the company collaborated with Substipharm Biologics to expand ENVACGEN distribution in Southeast Asia; it filed a new drug application for its enterovirus 71 vaccine in Vietnam in 2023 and partnered with the WHO C-TAP Initiative that year to out-license COVID-19 technology globally.